Pharmaceutical company Eli Lilly has informed us that all strengths of Mounjaro (tirzepatide) vials are now discontinued due to commercial reasons and supply of all vial presentations has been exhausted. Further information about the discontinuations is available on the TGA’s Medicine Shortage Reports Database.
Please note:
- this discontinuation only affects the vial presentation
- Mounjaro KwikPen is available and there are no reported supply issues with any strength of Mounjaro KwikPen at present
- Mounjaro KwikPens cannot be dispensed using a prescription for the vial presentation, so patients requiring the KwikPen will need a new prescription.
The KwikPen presentation is a multi-dose, pre-filled pen containing the same dosage amounts as the pre-existing Mounjaro vials (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg). The KwikPen is also approved for the treatment of type 2 diabetes and chronic weight management.
For more information about the supply of Mounjaro products, you can contact Eli Lilly on 1800 454 559.
Featured in
Product types